Answers are grounded in this paper and cite their sources.
Melflufen is a novel cytostatic currently in phase III clinical trials for treatment of multiple myeloma. Development of a process suitable for production is described. The two key features of the novel method are late introduction of the alkylating pharmacophore and an improved method for formation of the bis-chloroethyl group.
No takes yet. Share an insight, caveat, or question.
Cotton et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: